Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12419
Title: Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Austin Authors: Johnson, Douglas B;Flaherty, Keith T;Weber, Jeffrey S;Infante, Jeffrey R;Kim, Kevin B;Kefford, Richard F;Hamid, Omid;Schuchter, Lynn;Cebon, Jonathan S ;Sharfman, William H;McWilliams, Robert R;Sznol, Mario;Lawrence, Donald P;Gibney, Geoffrey T;Burris, Howard A;Falchook, Gerald S;Algazi, Alain;Lewis, Karl;Long, Georgina V;Patel, Kiran;Ibrahim, Nageatte;Sun, Peng;Little, Shonda;Cunningham, Elizabeth;Sosman, Jeffrey A;Daud, Adil;Gonzalez, Rene
Affiliation: Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. douglas.b.johnson@vanderbilt.edu.
Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Heidelberg, Victoria, Australia
Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.
Issue Date: 6-Oct-2014
Publication information: Journal of Clinical Oncology 2014; 32(33): 3697-704
Abstract: Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had received prior BRAF inhibitor treatment.In this open-label phase I/II study, we evaluated the pharmacology, safety, and efficacy of dabrafenib and trametinib. Here, we report patients treated with combination therapy after disease progression with BRAF inhibitor treatment administered before study enrollment (part B; n = 26) or after cross-over at progression with dabrafenib monotherapy (part C; n = 45).In parts B and C, confirmed objective response rates (ORR) were 15% (95% CI, 4% to 35%) and 13% (95% CI, 5% to 27%), respectively; an additional 50% and 44% experienced stable disease ≥ 8 weeks, respectively. In part C, median progression-free survival (PFS) was 3.6 months (95% CI, 2 to 4), and median overall survival was 11.8 months (95% CI, 8 to 25) from cross-over. Patients who previously received dabrafenib ≥ 6 months had superior outcomes with the combination compared with those treated < 6 months; median PFS was 3.9 (95% CI, 3 to 7) versus 1.8 months (95% CI, 2 to 4; hazard ratio, 0.49; P = .02), and ORR was 26% (95% CI, 10% to 48%) versus 0% (95% CI, 0% to 15%).Dabrafenib plus trametinib has modest clinical efficacy in patients with BRAF inhibitor-resistant melanoma. This regimen may be a therapeutic strategy for patients who previously benefited from BRAF inhibitor monotherapy ≥ 6 months but demonstrates minimal efficacy after rapid progression with BRAF inhibitor therapy.
Gov't Doc #: 25287827
URI: http://ahro.austin.org.au/austinjspui/handle/1/12419
DOI: 10.1200/JCO.2014.57.3535
URL: https://pubmed.ncbi.nlm.nih.gov/25287827
Type: Journal Article
Subjects: Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols.therapeutic use
Disease Progression
Disease-Free Survival
Female
Humans
Imidazoles.administration & dosage.adverse effects
Male
Melanoma.drug therapy.genetics.mortality
Middle Aged
Mitogen-Activated Protein Kinase Kinases.antagonists & inhibitors
Mutation
Oximes.administration & dosage.adverse effects
Protein Kinase Inhibitors.administration & dosage.therapeutic use
Proto-Oncogene Proteins B-raf.antagonists & inhibitors.genetics
Pyridones.administration & dosage.adverse effects
Pyrimidinones.administration & dosage.adverse effects
Appears in Collections:Journal articles

Show full item record

Page view(s)

14
checked on Nov 28, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.